Overview
Richard Clutton practices practicing medicine in Roslin, United Kingdom.
His clinical expertise encompasses Lung Adenocarcinoma, Compartment Syndrome, and Cerebral Hypoxia.
He is actively involved in clinical research, co-authoring 59 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Richard E. Clutton
Is Richard E. Clutton a top-rated expert for Lung Adenocarcinoma?
MediFind is an objective health platform that identifies experts based on real-world data. Richard E. Clutton is classified as an Experienced expert for Lung Adenocarcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Richard E. Clutton participate in research or clinical trials?
Yes. Richard E. Clutton has published 59 articles and abstracts on conditions like Lung Adenocarcinoma. You can view a list of Richard E. Clutton's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Cerebral HypoxiaMr. Clutton isExperienced. Learn about Cerebral Hypoxia.
- Compartment SyndromeMr. Clutton isExperienced. Learn about Compartment Syndrome.
- Lung AdenocarcinomaMr. Clutton isExperienced. Learn about Lung Adenocarcinoma.